Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Oct 19 2018

• By Joseph Haas and Kevin Grogan

Handshake of businessmen

Related Content

Vertex’s Danish Reimbursement Deal Brings Budget Predictability

Oct 16 2018

BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration

Oct 16 2018

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

Oct 18 2018

Tie-Up Moves Kangstem's Novel Stem Cell Therapy Towards Globalization

Oct 17 2018

Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?

Oct 12 2018

Carrick Targets Ovarian Cancer With BTG Deal, Entices Celgene’s Former Top Deal Maker

Oct 11 2018

Ionis Catches The Eye With New Roche Alliance

Oct 11 2018

Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio

Aug 03 2018

Oxford Nanopore Hits £1.5bn Valuation With Latest £100m Round

Mar 22 2018

Related Companies

Amgen, Inc.

Oxford Nanopore Technologies plc

Aclaris Therapeutics, Inc.

Allergan plc

Almirall SA

Roche Holding AG

SQZ Biotechnologies Company

AstraZeneca PLC

Jnana Therapeutics Inc.

Neurocrine Biosciences, Inc.

Sarepta Therapeutics, Inc.

Lysogene SA

Lacerta Therapeutics, Inc.

Myonexus Therapeutics, Inc.

Morphic Therapeutic, Inc.

AbbVie Inc.

MaSTherCell Global Inc.

Bristol Myers Squibb Company

Compugen Ltd.

Vertex Pharmaceuticals Incorporated

Novartis AG

Carrick Therapeutics, Inc.

Bristol Myers Squibb Company

Ionis Pharmaceuticals, Inc.

Additional Topics

Deals Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window